Infinimmune lands $75M Series A to push eczema antibodies forward
TL;DR Summary
Biotech startup Infinimmune raises $75 million in a Series A led by Regeneron Ventures (with Playground Global) to advance its human B cell–based antibody platform for eczema, including lead antibodies IFX-201 and IFX-101 moving to Phase 1 next year. Regeneron’s investment aims to complement Dupixent, Merck remains an investor, and the company envisions additional large‑pharma partnerships as it advances its pipeline.
- Regeneron backs $75M series A for antibody upstart Infinimmune Fierce Biotech
- Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M Endpoints News
- Infinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease Business Wire
- Re-engineering immune memory for tissue repair Longevity.Technology
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczema BioPharma Dive
Reading Insights
Total Reads
0
Unique Readers
6
Time Saved
2 min
vs 3 min read
Condensed
87%
453 → 61 words
Want the full story? Read the original article
Read on Fierce Biotech